Published in Hepatitis Weekly, July 11th, 2005
The study enrolled 460 healthy subjects aged 18 to 49 into three equal arms at three sites in the United States during the 2004/05 influenza season. Subjects received one of the two different doses of FluBlOk (the concentration of the H1 and B antigens was different and the H3 antigen the same in the two FluBlOk formulations) or placebo. The study subjects were followed for influenza-like illnesses (ILI) and those who developed ILI...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.